The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “PhD Student”
Reference: Ref. 14-2022
Application deadline: 31.03.2022
Number of vacancies: 1
The Vall d´Hebron Institute of Oncology´s (VHIO) Gastrointestinal and Endocrine Tumor Group, headed by Dr. Teresa Macarulla, is recruiting a Ph.D. student.
Our group is interested in seeking out prognostic and predictive factors related to targeted and immune therapies as well as identifying new response and resistance markers. Previously, our group has actively participated in developing molecular therapies targeting altered signaling pathways of colorectal, pancreatic, gastric, neuroendocrine, and bile duct cancers (cholangiocarcinoma), among others. The group has pioneered early phase clinical trials to potentiate novel anti-cancer strategies against GI cancers and translational studies associated with these novel therapeutic approaches, including biomarker discovery. Our preclinical team is currently led by Dr. Tian Tian and is interested in epigenetic features that can be used in gastrointestinal and hepatobiliary cancer diagnosis and treatment. Moreover, the group has established both in vivo and ex vivo models to study hepatobiliary cancer biology and evaluate novel treatments.
We are looking for an enthusiastic Ph.D. student willing to participate in our translational project, which is at the interface of clinical and preclinical studies. The student will have the opportunity to work with a large variety of high-throughput techniques to study epigenetic dysregulations found in GI cancer patients (e.g., RNA-seq, ChIP-seq, ATAC-seq, MeDIP-seq) as well as the use of patient-derived preclinical models to perform drug screens ex vivo and in vivo. Moreover, we encourage the student to acquire bioinformatic competence to perform genome-wide data analysis.
- This offer is open to candidates of any nationality.
- Candidates must have obtained a Bachelor’s Degree and a Master’s Degree in biomedical sciences or an equivalent University Degree (European Education System minimum 300ECTS), allowing them to start a Ph.D. thesis in the candidate´s home country by September 2022.
- Candidates who expect to be awarded such a degree (Master’s Degree is ongoing) by September 2022 are eligible to apply.
- Candidates must have an excellent academic record.
- Candidates must have high working knowledge of English.
- Previous research experience in biomedicine is a plus.
- To be successful in this application, the candidate will be a very organized, motivated, team-oriented individual.
- Salary will be negotiated according to the institutional guideline.
- Start date: September 2022
Candidates must submit a curriculum vitae and letter of intent and the contact information of two references addressed to Dr. Teresa Macarulla and Dr. Tian Tian using the form below or via email to: firstname.lastname@example.org, including the reference “Ref.14-2022” in the subject line of your email.
Review of applications will commence immediately; interviews will be arranged with short-listed candidates.
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO), has established itself as a comprehensive cancer center of proven excellence internationally. It is also thanks to VHIO’s optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease.
Located within the Vall d’Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d’Hebron physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients.
VHIO’s pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread, and more effectively treating even the most undruggable tumor types.
VHIO’s translation toward precision oncology: https://www.vhio.net
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.